

**From:** Do, Yu  
**To:** ["James Maloney"](#)  
**Subject:** Information Request (Response Due by Friday, February 22, 2019): Class 2 Resubmission, BL 125590/0, Immune Globulin Intravenous (Human), 10% Liquid, ADMA Biologics, Inc.  
**Date:** Tuesday, February 12, 2019 4:04:00 PM  
**Attachments:** [image001.png](#)  
**Importance:** High

---

Dear Mr. Maloney:

We are reviewing your resubmission of September 28, 2018, to BL 125590/0 for Immune Globulin Intravenous (Human), 10% Liquid. We determined that the following information is necessary to continue our review:

Assay for (b) (4)

1. In Amendment 42, Response to Complete Response Letter (CR) dated July 29, 2016, submitted to STN BL 125590/0 for Immune Globulin Intravenous (Human), 10% Liquid, you indicated that you are working with (b) (4) to develop a method for measuring (b) (4) in your Immune Globulin Intravenous (Human), 10% product (RI-002) using an (b) (4) assay and that you will implement the (b) (4) assay, instead of the current (b) (4) assay as soon as validation of the method is completed which was expected to be by the end of December 2018.

In Amendment 47 submitted to STN BL 125590 on December 21, 2018, Response to FDA Request for Information – Testing and Analytical Assays – 11 December 2018, you provided a list of changes you made to the analytical methods used for RI-002 drug substance and final container drug product since the issuance of the CR letter dated July 29, 2016. However, you did not include (b) (4) assay in your list.

To this date we have not received the test procedure and method validation report for the (b) (4) method. Please provide the detailed test method for the (b) (4) method and the method validation results for review, if you intend to use this method for the determination of (b) (4) in your Immune Globulin Intravenous (Human), 10% product (RI-002) for lot-release.

2. If you intend to use the (b) (4) assay for the determination of (b) (4) instead of the (b) (4) assay method, please provide data to evaluate effect of small deliberate changes of critical method parameters, such as reagent concentration and incubation time, in order to demonstrate method robustness, as requested in the Complete Response letter.

The review of this submission is ongoing, and issues may be added, expanded upon, or modified as we continue to review this submission. Please submit your response as an amendment to this file (BL 125590/0) by February 22, 2019, referencing the date of this request. If you anticipate you will not be able to respond by this date, please contact the Agency immediately so a new response date can be identified.

If we determine that your response to this information request constitutes a major amendment,

we will notify you in writing.

The action due date for this file is April 2, 2019.

Please acknowledge receipt of this request and contact me at (240) 402-8343 or [Yu.Do@fda.hhs.gov](mailto:Yu.Do@fda.hhs.gov) if you have any questions.

Sincerely,

Yu Do, M.S.  
Regulatory Project Manager  
Office of Tissues and Advanced Therapies  
Center for Biologics Evaluation and Research  
Office of Medical Products and Tobacco  
Food and Drug Administration  
(240) 402-8343  
[Yu.Do@fda.hhs.gov](mailto:Yu.Do@fda.hhs.gov)



"THIS MESSAGE IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify the sender by e-mail or phone."